Summary & Overview
HCPCS Level II J1600: Injection, Gold Sodium Thiomalate, up to 50 mg
HCPCS Level II code J1600 denotes an injectable formulation of gold sodium thiomalate, up to 50 mg, used as a disease-modifying antirheumatic therapy administered in outpatient settings. Nationally, this code matters for billing and coverage of parenteral DMARD treatments with specialized administration and monitoring needs. Payors commonly addressing this code include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise profile of clinical context and billing relevance, including the service type (injectable specialty pharmacologic therapy), typical sites of service (physician office or outpatient clinic), and the role of J1600 in coding administrations of gold-based DMARD injections. The publication outlines benchmarks and coverage considerations where available, summarizes common modifier usage patterns and payer-specific coverage approaches, and highlights policy or billing guidance that affects reimbursement and claim adjudication for injectable rheumatologic therapies. The document is intended for billing managers, revenue cycle staff, clinical administrators, and policy analysts seeking a national overview of coding and coverage touchpoints for J1600.
Billing Code Overview
HCPCS Level II code J1600 represents an injection of gold sodium thiomalate, up to 50 mg. This code corresponds to a parenteral disease-modifying antirheumatic drug (DMARD) formulation administered by injection.
-
Service type: Injectable specialty pharmacologic therapy
-
Typical site of service: Physician office or outpatient clinic for administered injections
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a middle-aged adult with rheumatoid arthritis or refractory inflammatory arthritis who has not tolerated or responded to first-line disease-modifying antirheumatic drugs (DMARDs) and is being treated with intramuscular gold sodium thiomalate. The service described by J1600 (Injection, gold sodium thiomalate, up to 50 mg) is administered in an outpatient infusion or procedure suite, a physician office, or an ambulatory care clinic by a rheumatologist or trained clinician. The clinical workflow includes: initial evaluation and documentation of diagnosis and prior therapies, informed consent discussing risks (local pain, allergic reaction, proteinuria), baseline laboratory testing (CBC, renal function, urinalysis), preparation of the injection, verification of dose and patient identity, administration via deep intramuscular injection, observation for immediate adverse reactions for an appropriate period, and documentation of lot number, dose, site, and patient tolerance. Follow-up involves scheduled monitoring labs and assessment of therapeutic response and adverse effects at subsequent visits.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier (default) | Use when no special circumstances apply to the service. |